Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification
暂无分享,去创建一个
Melissa A. Troester | Mark E. Sherman | Andrew F. Olshan | Julie R. Palmer | Joseph Geradts | Wiam Bshara | Xuezheng Sun | Christine B. Ambrosone | A. Olshan | J. Palmer | M. Sherman | W. Bshara | Mengjie Chen | T. Khoury | Xuezheng Sun | C. Ambrosone | M. Troester | J. Geradts | G. Zirpoli | Thaer Khoury | Emma H. Allott | Stephanie M. Cohen | Gary R. Zirpoli | Mengjie Chen | E. Allott
[1] A. Olshan,et al. Racial differences in physical activity among breast cancer survivors: Implications for breast cancer care , 2014, Cancer.
[2] Kornelia Polyak,et al. Heterogeneity in breast cancer. , 2011, The Journal of clinical investigation.
[3] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[4] C. Perou,et al. Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[5] C. Gomez-Fernandez,et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. , 2005, American journal of clinical pathology.
[6] Zhao-xiang Gu,et al. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis , 2012, Breast Cancer Research and Treatment.
[7] P. Klein,et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. , 2006, Clinical breast cancer.
[8] I. Ellis,et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast , 2006, Journal of Clinical Pathology.
[9] J. Bergh,et al. HER-2/neu (c-erbB-2) Evaluation in Primary Breast Carcinoma by Fluorescent In Situ Hybridization and Immunohistochemistry With Special Focus on Intratumor Heterogeneity and Comparison of Invasive and In Situ Components , 2004, Applied immunohistochemistry & molecular morphology : AIMM.
[10] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[11] E. Perez,et al. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study , 2014, Breast Cancer Research and Treatment.
[12] G. Wilding,et al. Delay to formalin fixation effect on breast biomarkers , 2009, Modern Pathology.
[13] B. Strom,et al. Breast Cancer Receptor Status: Do Results from a Centralized Pathology Laboratory Agree with SEER Registry Reports? , 2009, Cancer Epidemiology, Biomarkers & Prevention.
[14] M. Nerenberg,et al. Loss of antigenicity with tissue age in breast cancer , 2016, Laboratory Investigation.
[15] S. Nofech-Mozes,et al. Intratumoral Heterogeneity of HER2/neu in Breast Cancer—A Rare Event , 2007, The breast journal.
[16] A. Douglas-Jones,et al. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. , 2001, Journal of clinical pathology.
[17] Charles Swanton,et al. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine , 2014, Genome Biology.
[18] G. Wilding,et al. Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones. , 2010, American journal of clinical pathology.
[19] Jun Jiang,et al. Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis , 2012, Breast Cancer Research and Treatment.
[20] A. Olshan,et al. A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium , 2013, Cancer Causes & Control.
[21] Y. Oda,et al. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. , 2002, Human pathology.
[22] Charles Swanton,et al. Clinical management of breast cancer heterogeneity , 2015, Nature Reviews Clinical Oncology.
[23] R. Tamimi,et al. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. , 2008, Journal of the National Cancer Institute.
[24] Edith A Perez,et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Leong,et al. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. , 2001, American journal of clinical pathology.
[26] Peter A Kaufman,et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[28] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[29] L. Tafra,et al. Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? , 2013, Journal of the American College of Surgeons.
[30] U. Lehmann,et al. Marked Intratumoral Heterogeneity of c-myc and CyclinD1 But Not of c-erbB2 Amplification in Breast Cancer , 2002, Laboratory Investigation.
[31] M. Gnant,et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. , 2003, Endocrine-related cancer.
[32] D. Rimm,et al. Quantitative analysis of estrogen receptor heterogeneity in breast cancer , 2007, Laboratory Investigation.
[33] Päivi Heikkilä,et al. Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium , 2014, The journal of pathology. Clinical research.